High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study
Journal of Neural TransmissionPublished 23 October 2004
Michael Graf, D. Ecker, R. Horowski, Benjamin Krämer, Peter Riederer, M. Gerlach
Citations191
SJR quartileQ1
SJR score1.11
SNIP1.13
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Neither the primary nor the secondary outcome measures could determine whether a megadose of vitamin E is efficacious in slowing disease progression in ALS as an add-on therapy to riluzol.
Abstract
Neither the primary nor the secondary outcome measures could determine whether a megadose of vitamin E is efficacious in slowing disease progression in ALS as an add-on therapy to riluzol. Larger or longer studies might be needed. However, administration of this megadose does not seem to have any significant side effects in this patient population.
Keywords
MedicineNeuroscience
NatureMutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis
7,046 Citations1993D.R. Rosen, Teepu Siddique +31 more
Tight genetic linkage between FALS and a gene that encodes a cytosolic, Cu/Zn-binding superoxide dismutase (SOD1), a homodimeric metalloenzyme that catalyzes the dismutation of the toxic superoxide anion O2.- to O2 and H2O2 is reported.
Medical CareThe Sickness Impact Profile: Development and Final Revision of a Health Status Measure
4,655 Citations1981Marilyn Bergner, Ruth A. Bobbitt +2 more
The final development of the Sickness Impact Profile (SIP), a behaviorally based measure of health status, is presented and a technique for describing and assessing similarities and differences among groups was developed using profile and pattern analysis.
New England Journal of MedicineA Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
2,371 Citations1997Mary Sano, Christopher Ernesto +10 more
In patients with moderately severe impairment from Alzheimer's disease, treatment with selegiline or alpha-tocopherol slows the progression of disease.
New England Journal of MedicineA Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis
2,157 Citations1994Gilbert Bensimon, Lucette Lacomblez +1 more
The antiglutamate agent riluzole appears to slow the progression of amyotrophic lateral sclerosis, and it may improve survival in patients with disease of bulbar onset, according to a prospective, double-blind, placebo-controlled trial in 155 outpatients with Amyotrophicateral sclerosis.
Journal of NeurochemistryEvidence of Increased Oxidative Damage in Both Sporadic and Familial Amyotrophic Lateral Sclerosis
801 Citations1997Robert J. Ferrante, Susan Browne +7 more
Immunohistochemical studies showed increased neuronal staining for hemeoxygenase‐1, malondialdehyde‐modified protein, and OH8dG in both SALS and FALS spinal cord, providing further evidence that oxidative damage may play a role in the pathogenesis of neuronal degeneration in both FALS and SALS.
Annual Review of NutritionVitamin E: Antioxidant Activity, Biokinetics, and Bioavailability
752 Citations1990Graham W. Burton, Maret G. Traber
Pour mesurer l'absorption et le transport de la vitamine E, utilisation d'un isotope stable marque et analyse par chromatographie gazeuse et spectrometrie de masse.
Annals of NeurologyBenefit of vitamin E, riluzole, and gababapentin in a transgenic model of familial amyotrophic lateral sclerosis
650 Citations1996Mark E. Gurney, Frank B. Cutting +5 more
The hypothesis that oxidative damage produced by the expression of mutant Cu,Zn SOD causes slow or weak excitotoxicity that can be inhibited in part by altering glutamate release or biosynthesis presynaptically is suggested.
Annals of NeurologyIncreased 3‐nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis
595 Citations1997M. Flint Beal, Robert J. Ferrante +4 more
Annals of NeurologyImpact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa
359 Citations1996Parkinson Study Group
It is concluded that prior treatment with deprenyl or tocopherol did not reduce the occurrence of subsequent levodopa-associated adverse effects in this population of patients with Parkinson's disease.
Journal of the Neurological SciencesOnset, natural history and outcome in idiopathic adult motor neuron disease
301 Citations1993Forbes H. Norris, Rodger Shepherd +6 more
Among 708 cases aged 25-74 years at onset, the most common type was typical, sporadic amyotrophic lateral sclerosis (SporALS), and Familial ALS (FamALS) was diagnosed in 7%.
Journal of NeurologyGlutamate, excitotoxicity and amyotrophic lateral sclerosis
295 Citations1997Pamela J. Shaw, Paul G. Ince
Eight lines of evidence that indicate a disturbance of glutamatergic neurotransmission in ALS patients are reviewed and the links between abnormal activation of glutamate receptors and other potential mechanisms of neuronal injury, including activation of calcium-mediated second messenger systems and free radical mechanisms, are emphasised.
NeurologyThe administration of guanidine in amyotrophic lateral sclerosis
282 Citations1974FORBES H. NORRIS, Philip R. Calanchini +3 more
Empirical treatment of patients with amyotrophic lateral sclerosis suggested that some modification of the classical downhill course occurred in nonfamilial cases during administration of guanidine hydrochloride in dosages of at least 10 mg per kilogram per day for three months or more.
BrainMitochondrial DNA abnormalities in skeletal muscle of patients with sporadic amyotrophic lateral sclerosis
262 Citations2000Stefan Vielhaber
The results support the viewpoint that an oxygen radical-induced impairment of mtDNA is of pathophysiological significance in the aetiology of at least a subgroup of patients with SALS.
Amyotrophic Lateral Sclerosis and Other Motor Neuron DisordersA double-blind, placebo-controlled randomized clinical trial of α-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis
259 Citations2001Claude Desnuelle, Michel Dib +2 more
Although f -tocopherol did not appear to affect the survival and motor function in ALS, patients receiving riluzole plus f -ocopherol remained longer in the milder states of the ALS Health State scale and showed changes in biochemical markers of oxidative stress.
NeurologyThe natural history of amyotrophic lateral sclerosis
241 Citations1993S. P. Ringel, J. R. Murphy +18 more
There was a highly variable rate of decline within the group of patients and decline in pulmonary function most closely correlated with death, and one possible strategy is to identify and stratify patients by rate of declined pulmonary function since prospectively identifying homogeneous subgroups allows investigators to substantially reduce sample size in therapeutic trials.
NeurologyIntakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk
238 Citations2002Shuhua Zhang, Miguel A. Hernán +4 more
The reduction in risk of PD associated with high dietary vitamin E intake suggests that other constituents of foods rich in vitamin E may be protective, but this benefit may be lost with higher intakes.
Brain PathologyOxidative Stress and Motor Neurone Disease
225 Citations1999Mark Cookson, Pamela J. Shaw
Future research will need to identify the aspects of the molecular and physiological phenotype of human motor neurones that makes them susceptible to degeneration in MND, and to identify those genetic and environmental factors which combine to cause this disease in individuals and in familial pedigrees.
PubMedDATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism.
156 Citations1998Ira Shoulson
Deprenyl 10 mg/day was found to significantly delay the time until enough disability developed to warrant the initiation of levodopa therapy, and this effect was largely sustained during the overall 8.2 years of observation.
Birkhäuser Basel eBooksAnalysis of Free Radicals in Biological Systems
156 Citations1995Alain Favier, Jean Cadet +3 more
Methodological and practical aspects for in vitro studies of oxidative stress on cell culture models (toxicity and protection) are studied.
Mayo Clinic ProceedingsMotor Neuron Disease (Amyotrophic Lateral Sclerosis)
153 Citations1991David B. Williams, Anthony J. Windebank
The clinical limits of the disease can now be better defined by using modern diagnostic techniques, and the widely developing perception that it is a disease of elderly persons more than of middle-aged adults as was previously taught is changed.
NeurologyAlpha-tocopherol in the ventricular cerebrospinal fluid of Parkinson's disease patients
77 Citations1996Eric J. Pappert, Christy Tangney +5 more
To determine if ventricular cerebrospinal fluid (vCSF) alpha-tocopherol levels in Parkinson's disease patients can be increased by oral alpha-ocopherol supplementation and whether vCSF levels are linearly related to plasma alpha-atechol-like levels, a dose-response curve was established and there was no correlation between plasma and v CSF alpha-TCP levels.
NeurologyA double‐blind, placebo‐controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis
64 Citations1989Lucette Lacomblez, P. Bouché +2 more
Though this dosage had no major toxic effect, Cronassial treatment did not significantly benefit ALS patients and was not effective in any of the outpatients.
Neurologic ClinicsCLINICAL EPIDEMIOLOGY OF AMYOTROPHIC LATERAL SCLEROSIS
59 Citations1996Benjamin Rix Brooks
Better understanding of the age-specific presentation of motor neuron diseases worldwide will shed light on the vexing questions concerning the variable incidence rates in some countries and apparent incidence gradients in North America and Europe.
PubMedGlutathione peroxidase in amyotrophic lateral sclerosis: the effects of selenium supplementation.
59 Citations1998Slobodan Apostolski, Z Marinković +4 more
A disturbed oxidative/antioxidative balance in sALS patients exists not only in motoneurons but also in the blood, and only the use of all components together enhanced the activity of GSH-Px and the amount of vitamin E in s ALS patients.
NeurodegenerationBlood Superoxide Dismutase, Catalase and Glutathione Peroxidase Activities in Familial and Sporadic Amyotrophic Lateral Sclerosis
54 Citations1996Serge Przedborski, David M. Donaldson +6 more
Measurements of erythrocyte activity of the three main free radical scavenging enzymes: copper/zinc superoxide dismutase (Cu/Zn-SOD), catalase, and glutathione peroxidase are reported on to indicate that disturbances ofCatalase and glutathonase function are not likely to be central factors in the pathogenesis of ALS.
NeurologySerum levels of alpha‐tocopherol (vitamin E) in Parkinson's disease
51 Citations1992Pilar Fernández–Calle, J. A. Molina +7 more
Serum levels of the vitamin E and vitamin E/cholesterol ratio did not correlate with age age at onset, scores of the Unified Parkinson's Disease Rating Scale or the Hoehn and Yahr staging in the PD group, suggesting that serum vitamin E concentrations do not play a role in the pathogenesis of PD.
Archives of NeurologyReduced Risk of Alzheimer Disease in Users of Antioxidant Vitamin Supplements
47 Citations2004Peter P. Zandi
Journal of the Neurological SciencesPlasma superoxide dismutase and glutathione peroxidase activity in sporadic amyotrophic lateral sclerosis
36 Citations1997Radouane Moumen, André Nouvelot +3 more
Increased plasma SOD activity might reflect the involvement of extra-cellular SOD (SOD3), a hitherto unreported finding in SALS, and increased MDA concentration provides indirect confirmation of excess lipoperoxydation.